A Post-marketing Database Surveillance to Investigate the Risk of Rhabdomyolysis and Myopathy in Hypercholesterolemic Patients Treated with ATOZET or Ezetimibe Atorvastatin coadministration in Japan (MK-0653C-854)

First published 15/06/2021

Last updated 23/04/2024

EU PAS number:

EUPAS41341

Study

Finalised

Documents

Study protocol

Initial protocol

MK-0653C-854-00-v2-Final Redaction

English (1.44 MB - PDF)View document

Study results

MK-0653C-854-CSR_final redaction

English (2.68 MB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs